The global dialysis machines and consumables market is expected to reach USD 23.22 billion by 2031 from USD 16.41 billion in 2023, growing at a CAGR of 4.6% in the forecast period of 2024 to 2031.
Market Segmentation
Global Dialysis Machines and Consumables Market, By Type (Hemodialysis and Peritoneal), Product Type (Hemodialysis and Peritoneal Dialysis), Disease Type (Chronic and Acute), End Use (Hospitals, Dialysis Centers, Home Care Settings, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Dialysis Machines and Consumables Market Dynamics
- Driver
- Increasing prevalence of kidney diseases
- Restraint
- High cost of treatment in developing countries
- Opportunity
- Government initiatives for various renal-related problems
Market Players
Some of the major market players operating in the global dialysis machines and consumables market are:
- Fresenius SE & Co. KGaA
- Baxter
- NIPRO
- Evoqua Water Technologies LLC
- Medtronic
- B. Braun SE
- Nikkiso Co., Ltd.
- JMS Co. Ltd.
- Jafron Biomedical Co., Ltd.
- Asahi Kasei Medical Co., Ltd.
- Atlantic Biomedical
- dialifegroup
- Advin Health Care
TABLE OF CONTENTS
1 INTRODUCTION 74
- 1.1 OBJECTIVES OF THE STUDY 74
- 1.2 MARKET DEFINITION 74
- 1.3 OVERVIEW OF THE GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET 74
- 1.4 CURRENCY AND PRICING 76
- 1.5 LIMITATIONS 76
- 1.6 MARKETS COVERED 76
2 MARKET SEGMENTATION 79
- 2.1 MARKETS COVERED 79
- 2.2 GEOGRAPHICAL SCOPE 80
- 2.3 YEARS CONSIDERED FOR THE STUDY 81
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 82
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 85
- 2.6 MULTIVARIATE MODELLING 86
- 2.7 MARKET APPLICATION COVERAGE GRID 87
- 2.8 PRODUCT LIFELINE CURVE 88
- 2.9 DBMR MARKET POSITION GRID 89
- 2.10 VENDOR SHARE ANALYSIS 90
- 2.11 SECONDARY SOURCES 91
- 2.12 ASSUMPTIONS 91
3 EXECUTIVE SUMMARY 92
4 PREMIUM INSIGHTS 94
- 4.1 PESTEL ANALYSIS 95
- 4.2 PORTER'S FIVE FORCES 96
5 MARKET OVERVIEW 97
- 5.1 DRIVERS 99
- 5.1.1 INCREASING PREVALENCE OF KIDNEY DISEASES 99
- 5.1.2 GROWING DEMAND FOR HOME-BASED DIALYSIS TREATMENTS 100
- 5.1.3 INCREASING AWARENESS ABOUT KIDNEY DISEASES 101
- 5.1.4 FAVORABLE REIMBURSEMENT POLICIES FOR DIALYSIS TREATMENT IN DEVELOPED COUNTRIES 101
- 5.2 RESTRAINTS 102
- 5.2.1 HIGH COST OF TREATMENT IN DEVELOPING COUNTRIES 102
- 5.2.2 RISK OF BLOODSTREAM INFECTIONS IN PATIENTS UNDERGOING DIALYSIS TREATMENT 103
- 5.2.3 AVAILABILITY OF KIDNEY TRANSPLANTATION AS AN ALTERNATIVE TREATMENT 104
- 5.3 OPPORTUNITIES 105
- 5.3.1 GOVERNMENT INITIATIVES FOR VARIOUS RENAL-RELATED PROBLEMS 105
- 5.3.2 STRATEGIC PARTNERSHIPS AMONG THE KEY MARKET PLAYERS 105
- 5.3.3 GROWING ADOPTION OF TECHNOLOGICALLY ADVANCED PRODUCTS 106
- 5.4 CHALLENGES 107
- 5.4.1 SHORTAGE OF SKILLED WORKFORCE FOR CONDUCTING THE DIALYSIS PROCEDURE 107
- 5.4.2 STRICT REGULATIONS IMPOSED BY THE GOVERNMENT AUTHORITIES 108
6 GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET, BY TYPE 110
- 6.1 OVERVIEW 111
- 6.2 HEMODIALYSIS 114
- 6.2.1 SHORT DAILY HEMODIALYSIS 114
- 6.2.2 CONVENTIONAL HEMODIALYSIS 114
- 6.2.3 NOCTURNAL HEMODIALYSIS 114
- 6.3 PERITONEAL 115
- 6.3.1 AUTOMATED PERITONEAL DIALYSIS 115
- 6.3.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 115
7 GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET, BY PRODUCT TYPE 116
- 7.1 OVERVIEW 117
- 7.2 HEMODIALYSIS 120
- 7.2.1 CONSUMABLES 121
- 7.2.2 MACHINE 122
- 7.3 PERITONEAL DIALYSIS 123
8 GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET, BY DISEASE TYPE 125
- 8.1 OVERVIEW 126
- 8.2 CHRONIC 129
- 8.2.1 HEMODIALYSIS 129
- 8.2.1.1 SHORT DAILY HEMODIALYSIS 130
- 8.2.1.2 CONVENTIONAL HEMODIALYSIS 130
- 8.2.1.3 NOCTURNAL HEMODIALYSIS 130
- 8.2.2 PERITONEAL 130
- 8.2.2.1 AUTOMATED PERITONEAL DIALYSIS 130
- 8.2.2.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 130
- 8.3 ACUTE 131
- 8.3.1 HEMODIALYSIS 131
- 8.3.1.1 SHORT DAILY HEMODIALYSIS 132
- 8.3.1.2 CONVENTIONAL HEMODIALYSIS 132
- 8.3.1.3 NOCTURNAL HEMODIALYSIS 132
- 8.3.2 PERITONEAL 132
- 8.3.2.1 AUTOMATED PERITONEAL DIALYSIS 132
- 8.3.2.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 132
9 GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET, BY END USE 133
- 9.1 OVERVIEW 134
- 9.2 HOSPITALS 137
- 9.2.1 CHRONIC 137
- 9.2.2 ACUTE 137
- 9.3 DIALYSIS CENTERS 138
- 9.3.1 CHRONIC 138
- 9.3.2 ACUTE 138
- 9.4 HOME CARE SETTINGS 139
- 9.4.1 CHRONIC 139
- 9.4.2 ACUTE 139
- 9.5 OTHERS 140
10 GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET, BY DISTRIBUTION CHANNEL 141
- 10.1 OVERVIEW 142
- 10.2 DIRECT TENDERS 145
- 10.3 RETAIL SALES 145
- 10.4 OTHERS 146
11 GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET, BY REGION 147
- 11.1 OVERVIEW 148
- 11.2 NORTH AMERICA 151
- 11.2.1 U.S. 161
- 11.2.2 MEXICO 171
- 11.2.3 CANADA 181
- 11.3 EUROPE 192
- 11.3.1 GERMANY 204
- 11.3.2 FRANCE 214
- 11.3.3 TURKEY 224
- 11.3.4 BELGIUM 235
- 11.3.5 SPAIN 246
- 11.3.6 SWITZERLAND 256
- 11.3.7 U.K. 266
- 11.3.8 NETHERLANDS 276
- 11.3.9 ITALY 287
- 11.3.10 RUSSIA 298
- 11.3.11 REST OF EUROPE 308
- 11.4 ASIA-PACIFIC 309
- 11.4.1 JAPAN 320
- 11.4.2 SOUTH KOREA 330
- 11.4.3 CHINA 341
- 11.4.4 INDIA 352
- 11.4.5 MALAYSIA 362
- 11.4.6 THAILAND 373
- 11.4.7 AUSTRALIA 384
- 11.4.8 SINGAPORE 395
- 11.4.9 INDONESIA 405
- 11.4.10 PHILIPPINES 415
- 11.4.11 REST OF ASIA-PACIFIC 426
- 11.5 MIDDLE EAST AND AFRICA 427
- 11.5.1 SOUTH AFRICA 438
- 11.5.2 SAUDI ARABIA 449
- 11.5.3 U.A.E. 460
- 11.5.4 EGYPT 470
- 11.5.5 ISRAEL 481
- 11.5.6 REST OF MIDDLE EAST AND AFRICA 492
- 11.6 SOUTH AMERICA 493
- 11.6.1 BRAZIL 504
- 11.6.2 ARGENTINA 515
- 11.6.3 REST OF SOUTH AMERICA 526
12 GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET: COMPANY LANDSCAPE 527
- 12.1 COMPANY SHARE ANALYSIS: GLOBAL 527
- 12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 528
- 12.3 COMPANY SHARE ANALYSIS: EUROPE 529
- 12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 530
13 SWOT ANALYSIS 531
14 COMPANY PROFILE 532
- 14.1 FRESENIUS SE & CO. KGAA 532
- 14.1.1 COMPANY SNAPSHOT 532
- 14.1.2 REVENUE ANALYSIS 532
- 14.1.3 COMPANY SHARE ANALYSIS 533
- 14.1.4 PRODUCT PORTFOLIO 533
- 14.1.5 RECENT DEVELOPMENT 534
- 14.2 BAXTER 535
- 14.2.1 COMPANY SNAPSHOT 535
- 14.2.2 REVENUE ANALYSIS 535
- 14.2.3 COMPANY SHARE ANALYSIS 536
- 14.2.4 PRODUCT PORTFOLIO 536
- 14.2.5 RECENT DEVELOPMENT 536
- 14.3 NIPRO 537
- 14.3.1 COMPANY SNAPSHOT 537
- 14.3.2 REVENUE ANALYSIS 537
- 14.3.3 COMPANY SHARE ANALYSIS 538
- 14.3.4 PRODUCT PORTFOLIO 538
- 14.3.5 RECENT DEVELOPMENT 538
- 14.4 EVOQUA WATER TECHNOLOGIES LLC 539
- 14.4.1 COMPANY SNAPSHOT 539
- 14.4.2 REVENUE ANALYSIS 539
- 14.4.3 COMPANY SHARE ANALYSIS 540
- 14.4.4 PRODUCT PORTFOLIO 540
- 14.4.5 RECENT DEVELOPMENT 541
- 14.5 MEDTRONIC 542
- 14.5.1 COMPANY SNAPSHOT 542
- 14.5.2 REVENUE ANALYSIS 542
- 14.5.3 COMPANY SHARE ANALYSIS 543
- 14.5.4 PRODUCT PORTFOLIO 543
- 14.5.5 RECENT DEVELOPMENT 544
- 14.6 ADVIN HEALTH CARE 545
- 14.6.1 COMPANY SNAPSHOT 545
- 14.6.2 PRODUCT PORTFOLIO 545
- 14.6.3 RECENT DEVELOPMENT 545
- 14.7 ASAHI KASEI MEDICAL CO., LTD. 546
- 14.7.1 COMPANY SNAPSHOT 546
- 14.7.2 REVENUE ANALYSIS 546
- 14.7.3 PRODUCT PORTFOLIO 547
- 14.7.4 RECENT DEVELOPMENT 548
- 14.8 ATLANTIC BIOMEDICAL 549
- 14.8.1 COMPANY SNAPSHOT 549
- 14.8.2 PRODUCT PORTFOLIO 549
- 14.8.3 RECENT DEVELOPMENT 550
- 14.9 B. BRAUN SE 551
- 14.9.1 COMPANY SNAPSHOT 551
- 14.9.2 PRODUCT PORTFOLIO 551
- 14.9.3 RECENT DEVELOPMENT 551
- 14.10 DIALIFEGROUP 552
- 14.10.1 COMPANY SNAPSHOT 552
- 14.10.2 PRODUCT PORTFOLIO 552
- 14.10.3 RECENT DEVELOPMENT 553
- 14.11 JAFRON BIOMEDICAL CO., LTD. 554
- 14.11.1 COMPANY SNAPSHOT 554
- 14.11.2 PRODUCT PORTFOLIO 554
- 14.11.3 RECENT DEVELOPMENT 554
- 14.12 JMS CO. LTD. 555
- 14.12.1 COMPANY SNAPSHOT 555
- 14.12.2 REVENUE ANALYSIS 555
- 14.12.3 PRODUCT PORTFOLIO 556
- 14.12.4 RECENT DEVELOPMENT 556
- 14.13 NIKKISO CO., LTD. 557
- 14.13.1 COMPANY SNAPSHOT 557
- 14.13.2 REVENUE ANALYSIS 557
- 14.13.3 PRODUCT PORTFOLIO 558
- 14.13.4 RECENT DEVELOPMENT 559
15 QUESTIONNAIRE 560
16 RELATED REPORTS 563